When, 5 years later, the American pharmacologist Raymond P. Ahlquist (1914–1983) proposed the existence of two types of adrenaline-receptors, alpha and beta, mediating different patterns of pharmacological action, his paper on this topic was rejected by the Journal of Pharmacology and Experimental Therapeutics. Through personal contacts with the editor of the American Journal of Physiology he eventually managed to get it published [25]. Ironically, Ahlquist's distinction between the two types of adrenaline-receptors became the basis for the development of the first therapeutically useful receptor blocking drug, the beta-blocker propranolol, which was introduced by (Sir) James Black in 1965. Only then did most pharmacologists start to believe that receptors were more than hypothetical entities, or as de Jongh had called them, ‘beautiful but remote ladies’.